9,437* participants enrolled at sites across the U.S., Europe and Canada in areas where Lyme disease is endemic Trial conclusion expected by year-end 2025 Pfizer aims to submit regulatory filings in ...
Pfizer and Valneva have completed recruitment for a phase 3 trial of the Lyme disease vaccine VLA15 after work was halted earlier this year due to problems with one of the CROs at some of the trial ...
New York, NY, and Saint-Herblain (France), December 4, 2023 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that they have completed recruitment for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results